To date, the most effective medical therapy in high-risk patients with moderate to severe CD seems to be combination anti-TNF and immunomodulator therapy, while endoscopic and surgical interventions remain important options as needed [104,105,106]. This evidence concerns the gene TNF and Cowden disease.